Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: Molecular mechanisms and clinical significance

Emerging Microbes and Infections

Volumn 3, Issue 9, 2014, Pages

  Yang, Hung Chih ^a,b   Kao, Jia Horng ^a,b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chronic hepatitis B; Covalently closed circular DNA; Hepatitis B virus; Interferon; Nucleos(t)ide analog

Indexed keywords

ANTIVIRUS AGENT; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; RELAXED CIRCULAR DNA; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; DISEASE ERADICATION; EPIGENETICS; HEPATITIS B; HEPATITIS B VIRUS; HISTORY; HUMAN; LIFE CYCLE; LIVER CELL; MICROBIAL KINETICS; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS TRANSCRIPTION;

HEPATITIS B VIRUS;

EID: 84919449705     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2014.64     Document Type: Review

References (110)

1. Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virusrelated hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv Cancer Res 2010; 108: 21-72.
2. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-1500.
3. Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formosan Med Assoc 2013; 112: 302-311.
4. Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int 2014; 34 Suppl 1: 112-119.
5. Ahn SH, Chan HL, Chen PJ et al. Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int 2010; 4: 386-395.
6. LiangY,JiangJ,SuMet al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011; 34: 344-352.
7. Perez-Cameo C, Pons M, Esteban R. New therapeutic perspectives in HBV: when to stop NAs. Liver Int 2014; 34 Suppl 1: 146-153.
8. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-308.
9. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 94: 907.
10. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-1108.
11. Loriot MA, Marcellin P, Walker F et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol 1997; 27: 251-258.
12. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-1742.
13. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-415.
14. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008; 134: 235-249.
15. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
16. Yan H, Zhong G, Xu G et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012; 1: e00049.
17. Moolla N, Kew M, Arbuthnot P. Regulatory elements of hepatitis B virus transcription. J Viral Hepat 2002; 9: 323-331.
18. Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription. J Viral Hepat 2010; 17: 527-536.
19. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986; 47: 451-460.
20. Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990; 175: 255-261.
21. Newbold JE, Xin H, Tencza M et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995; 69: 3350-3357.
22. Zhang YY, Zhang BH, Theele D, Litwin S, Toll E, Summers J. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci USA 2003; 100: 12372-12377.
23. Gao W, Hu J. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol 2007; 81: 6164-6174.
24. Guo H, Jiang D, Zhou T, Cuconati A, Block TM, Guo JT. Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation. J Virol 2007; 81: 12472-12484.
25. Guo H, Mao R, Block TM, Guo JT. Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol 2010; 84: 387-396.
26. Jones SA, Boregowda R, Spratt TE, Hu J. In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase. J Virol 2012; 86: 5134-5150.
27. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758.
28. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15: 133-143.
29. Marusawa H, Uemoto S, Hijikata M et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000; 31: 488-495.
30. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34: 194-203.
31. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170.
32. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611.
33. Hsu C, Tsou HH, Lin SJ et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 2014; 59: 2092-2100.
34. Raimondo G, Pollicino T, Romano L, Zanetti AR. A 2010 update on occult hepatitis B infection. Pathol Biol (Paris) 2010; 58: 254-257.
35. Civitico GM, Locarnini SA. The half-life of duck hepatitis B virus supercoiled DNA in congenitally infected primary hepatocyte cultures. Virology 1994; 203: 81-89.
36. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71: 9392-9399.
37. DandriM, Burda MR, Will H, Petersen J. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology 2000; 32: 139-146.
38. Hantz O, Parent R, Durantel D, Gripon P, Guguen-Guillouzo C, Zoulim F. Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocytelike cells. J Gen Virol 2009; 90(Pt 1): 127-135.
39. Zhu Y, Yamamoto T, Cullen J et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311-322.
40. Addison WR, Walters KA, Wong WW et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002; 76: 6356-6363.
41. Le Guerhier F, Pichoud C, Guerret S et al. Characterization of the antiviral effect of 29,39-dideoxy-29, 39-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model. Antimicrob Agents Chemother 2000; 44: 111-122.
42. Le Guerhier F, Pichoud C, Jamard C et al. Antiviral activity of beta-L-29,39-dideoxy- 29,39-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus. Antimicrob Agents Chemother 2001; 45: 1065-1077.
43. Reaiche GY, Le Mire MF, Mason WS, Jilbert AR. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis. Virology 2010; 406: 286-292.
44. Siliciano JD, Siliciano RF. A long-term latent reservoir forHIV-1: discovery and clinical implications. J Antimicrob Chemother 2004; 54: 6-9.
45. Kock J, Schlicht HJ. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol 1993; 67: 4867-4874.
46. Delmas J, Schorr O, Jamard C et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002; 46: 425-433.
47. Kock J, Baumert TF, Delaney WE 4th, Blum HE, von Weizsacker F. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology 2000; 38: 1410-1418.
48. Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595-605.
49. Boni C, Laccabue D, LamperticoP et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963-973.
50. Sung JJ, Wong ML, Bowden S et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897.
51. Wong DK, Yuen MF, YuanHet al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004; 40: 727-737.
52. Chisari FV, Mason WS, Seeger C. Virology. Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA". Science 2014; 344: 1237.
53. Chan HL, Wong VW, Tse AM et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-1468.
54. Tseng TC, Liu CJ, Su TH et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141: 517-525.
55. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013; 48: 13-21.
56. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006; 11: 909-916.
57. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49(5 Suppl): S103-S111.
58. Allweiss L, Volz T, Lutgehetmann M et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol 2014; 60: 500-507.
59. Lucifora J, Xia Y, Reisinger F et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014: 343: 1221-1228.
60. Wursthorn K, Lutgehetmann M, Dandri M et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684.
61. Hagiwara S, Kudo M, Osaki Y et al. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. J Med Virol 2013; 85: 987-995.
62. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-4402.
63. Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. Hepatology 1999; 29: 1863-1869.
64. Lewin SR, Ribeiro RM, Walters T et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. Hepatology 2001; 34: 1012-1020.
65. Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002; 37: 137-144.
66. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080.
67. Lande-Diner L, Zhang J, Ben-Porath I et al. Role of DNA methylation in stable gene repression. J Biol Chem 2007; 282: 12194-12200.
68. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128: 707-719.
69. Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus genes 1994; 8: 215-229.
70. Bock CT, Schwinn S, Locarnini S et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 2001; 307: 183-196.
71. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-592.
72. Pollicino T, Belloni L, Raffa G et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 2006; 130: 823-837.
73. Belloni L, Pollicino T, de Nicola F et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 2009; 106: 19975-19979.
74. Vivekanandan P, Thomas D, Torbenson M. Hepatitis B viral DNA is methylated in liver tissues. J Viral Hepat 2008; 15: 103-107.
75. Zhang Y, Li C, Zhang Y et al. Comparative analysis of CpG islands among HBV genotypes. PloS One 2013; 8: e56711.
76. Vivekanandan P, Thomas D, Torbenson M. Methylation regulates hepatitis B viral protein expression. J Infect Dis 2009; 199: 1286-1291.
77. Guo Y, Li Y, Mu S, Zhang J, Yan Z. Evidence that methylation of hepatitis B virus covalently closed circular DNA in liver tissues of patients with chronic hepatitis B modulates HBV replication. J Med Virol 2009; 81: 1177-1183.
78. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006; 44: 694-702.
79. Volz T, Lutgehetmann M, Wachtler P et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133: 843-852.
80. Belloni L, Allweiss L, Guerrieri F et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNAminichromosome. J Clin Invest 2012; 122: 529-537.
81. Liu F, Campagna M, Qi Y et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 2013; 9: e1003613.
82. Dandri M, Petersen J. Hepatitis B virus cccDNA clearance: killing for curing? Hepatology 2005; 42: 1453-1455.
83. Guidotti LG, Ando K, Hobbs MV et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 3764-3768.
84. Guidotti LG. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-829.
85. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65-91.
86. Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD81 T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol 2010; 184: 287-295.
87. McClaryH, Koch R, Chisari FV, Guidotti LG. Relative sensitivity of hepatitisBvirus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol 2000; 74: 2255-2264.
88. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25-36.
89. Jacquard AC, Nassal M, Pichoud C et al. Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 2004; 48: 2683-2692.
90. Zhu Y, Cullen JM, Aldrich CE et al. Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus. Virology 2004; 327: 26-40.
91. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004; 303: 1829.
92. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 2010; 17: 222-229.
93. Kitamura K, Wang Z, Chowdhury S, Simadu M, Koura M, Muramatsu M. Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA. PLoS Pathog 2013; 9: e1003361.
94. Thimme R, Wieland S, Steiger C et al. CD81 T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68-76.
95. Fourel I, Cullen JM, Saputelli J et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994; 68: 8321-8330.
96. Guo JT, Zhou H, Liu C et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infections. J Virol 2000; 74: 1495-1505.
97. Summers J, Jilbert AR, Yang W et al. Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci USA 2003; 100: 11652-11659.
98. Summers J, Mason WS. Residual integrated viralDNAafter hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 2004; 101: 638-640.
99. Mason WS, Jilbert AR, Summers J. Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci USA 2005; 102: 1139-1144.
100. Schiffer JT, Swan DA, Stone D, Jerome KR. Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach. PLoS Comput Biol 2013; 9: e1003131.
101. Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 2010; 18: 947-954.
102. Bloom K, Ely A, Mussolino C, Cathomen T, Arbuthnot P. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activatorlike effector nucleases. Mol Ther 2013; 21: 1889-1897.
103. Chen J, Zhang W, Lin J et al. An efficient antiviral strategy for targeting hepatitis B virus genome using Transcription Activator-Like Effector Nucleases. Mol Ther 2013: 22: 303-311.
104. Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods 2013; 10: 957-963.
105. Penna A, Chisari FV, Bertoletti A et al. Cytotoxic T lymphocytes recognize an HLA-A2- restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174: 1565-1570.
106. Nayersina R, Fowler P, Guilhot S et al. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 1993; 150: 4659-4671.
107. Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 1047-1058.
108. Bohne F, Protzer U. Adoptive T-cell therapy as a therapeutic option for chronic hepatitis B. J Viral Hepat 2007; 14 Suppl 1: 45-50.
109. Krebs K, Bottinger N, Huang LR et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 2013; 145: 456-465.
110. Schmidt WN, Nelson DR, Pawlotsky JM, Sherman KE, Thomas DL, Chung RT. Directacting antiviral agents and the path to interferon independence. Clin Gastroenterol Hepatol 2014; 12: 728-737.